Weight loss and malnutrition are major problems in patients with chronic graft-versus-host disease (GVHD). In adults, low body mass index (BMI) is a predictor for mortality; however, weight loss and BMI have not been studied in pediatric chronic GVHD. A retrospective study on 18 children with extensive chronic GVHD was completed. Median age at SCT was 12.3 (range 0.6-23) years; age at chronic GVHD diagnosis was 12.5 (1-23) years. Patients with multiorgan involvement had a mean maximal decrease in BMI of 20.9% and most dropped below 10th percentile in expected weight-for-age. This change in BMI not only indicates a significant decrease in weight but often a plateau in stature. In contrast, patients with one organ system involved had a mean maximal decrease in BMI of 5% and did not fall below 10th percentile. All patients with multiorgan involvement required salvage therapy beyond steroids and CSA. Three patients died due to complications of chronic GVHD. Weight loss and malnutrition (as reflected by a decrease in BMI) are clinically significant issues in children with multisystem chronic GVHD. Weight loss is likely another systemic manifestation of the disease and may contribute, along with other factors such as increased immunosuppression and infection, to increased mortality in this group.
Introduction
Chronic graft-versus-host disease (cGVHD), generally manifests itself in the skin, liver, lungs, joints, mouth, eyes and gastrointestinal tract causing lichenoid rashes and sclerodermatous changes to the skin, hepatitis, bronchiolitis obliterans, joint stiffness and contractures, lichenoid plaques in the mouth, dryness of the eyes and/or corneal abrasions, and moderate to severe gastrointestinal symptoms such as nausea, vomiting and profuse diarrhea. 1 Patients with cGVHD suffer from significant morbidity and mortality both from the disease as well as from long-term immunosuppression. 2 In pediatrics, the rates of cGVHD are about 22-29% of the total transplant population. 3 Although the rates of pediatric cGVHD are less than reported rates for adults, the overall rates of cGVHD are increasing in both pediatric and adults due to the use of alternative donors, peripheral blood stem cells (PBSC) and donor lymphocyte infusions (DLI) for patients at high risk for relapse of their primary disease. 4 One side effect that is often anecdotally reported by practitioners is chronic, intractable weight loss in pediatric patients with cGVHD. Although there is little research into this phenomenon in children, it has been observed in adults. Jacobsohn et al. reported that adults with active cGVHD have significant, long lasting decreases in weight and body mass index (BMI) despite nutritional supplementation and intervention. In addition, they found that when evaluated, over half of the patients studied were malnourished and 14% were severely malnourished with most of the severely malnourished patients also suffering from active cGVHD. 5 It has been shown that patients with a lower than normal BMI have an increased risk of mortality compared to those who are adequately nourished. 6 These observations indicate that weight loss in the cGVHD population is underreported, not well understood and may be a significant independent factor in morbidity and mortality in the post transplant setting.
The problem of continued and sustained weight loss despite intervention has been anecdotally observed in pediatric patients in our clinic. In an effort to better understand the extent of this weight loss, we performed a retrospective review of all patients diagnosed with extensive cGVHD at Children's Memorial Hospital. Our goal was to quantify the degree of weight loss as well as to examine changes in BMI and stature of our patients with cGVHD.
Methods
We performed a retrospective review of 18 patients at Children's Memorial Hospital with extensive cGVHD. Patients were then stratified into groups based on those who suffered from single organ of involvement versus those who suffered from more than one organ of involvement, based on clinical and/or histologic confirmation of organ involvement. (The five major organs used for this classification are: skin/musculoskeletal, liver, gastrointestinal, oral, and lung). Mean percent changes in weight and BMI (with 95% CI) were calculated for each group and compared using unpaired t-tests. Frequencies of specific organ involvement were compared using Fisher's Exact Test. Linear regression methods were used to compare weight and BMI between both groups, taking into account length of follow-up. P-values o0.05 were considered significant. Statistics were carried out using GraphPad Prism 4.0 and SPSS 11.0.
Results
The overall characteristics of the patients are detailed in Table 1 . All patients fit the criteria of extensive cGVHD Table 2 details changes in weight and BMI, as well as sites of involvement for patients with multiorgan versus single-organ cGVHD. Patients who had multiorgan involvement had a mean maximal decrease in their BMI of 20.9%. These patients also experienced a mean maximal decrease in weight of 16.6% from the time of transplant through their course of cGVHD. In comparison, patients with single organ involvement had a mean maximal decrease in BMI and weight of 5.0 and 6.6%, respectively. Of the eight evaluable patients who had more than one organ system involved (one was over 20 years so growth chart was not available), five patients had their BMI drop to less than the 10th% ile in weight-for age. In addition, many of these patients experienced a significant drop in their historical growth curves on heightfor-age growth charts. This downward trend in BMI not only indicates an overall trend of weight loss but in many cases a plateau in stature. It took a mean of 20.7 months from HSCT for this group of patients to reach their nadir BMI. With therapy, BMI improved in some patients, as the mean BMI change from transplant to current is À3.1%, much higher than the maximal BMI change of À20.9%.
Growth chart measurements for the patients with multiorgan involvement are outlined in Figures 1-4 . There were three patients whose age was outside the standard 2-to 20-year-old growth charts. One patient was a 19-month-old male with a À19% change in BMI from start of transplant to BMI nadir. The second was a 19-month-old male with a À17% change in BMI from the start of transplant to BMI nadir. The third was a 23-year-old male with a À31% change in BMI from the start of transplant to BMI nadir. or until last available data. ---Indicates patients who expired from complications of their cGVHD; -Indicates patient who is alive and stable with current cGVHD treatment; yy Indicates patient who at the onset of cGVHD had significant weight loss but who has had improvement of cGVHD symptoms with early treatment.
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We confirmed that differences in BMI and weight change between both groups were not due to a difference in length of follow-up. Single-organ patients had a mean follow-up of 36 (range 10-56) months and multiorgan patients had a mean follow-up of 29 (18-60) months. Linear regression analysis was used to compare weight and BMI change between both groups of patients, controlling for length of follow-up. Differences in maximal BMI and weight change remained statistically significant (Po0.0001, 0.003, respectively).
All of the patients with multi-organ involvement required salvage therapy beyond first-line immunosuppression with steroids and/or calcineurin inhibitor. Three patients died of complication of their chronic GVHD, and these patients had the most significant decreases in weight and BMI.
The patients who had only one organ system involved had a mean maximal change in BMI of À5% and a mean maximal change in weight of À6.6%. It took a mean of 6.1 months from HSCT for this group to reach their BMI nadir. None of these nine patients were less than the 10th% ile in weight-for-age and we did not observe the severe drop off in the historical growth curves that were observed in the patients with more than one organ system involved (figures not shown). There was one death in this group. After therapy there was also improvement in their BMI (8.1% mean change from HSCT to current in BMI and 11.7% change for weight).
Discussion
The etiology of the intractable weight loss remains without explanation although there are several theories that may explain the cause. During our review of these patients, it was observed that in several cases, weight loss preceded frank clinical symptoms of cGVHD. This observation Weight and BMI loss in pediatric cGVHD B Browning et al would indicate that these patients likely have alterations in metabolism that are not well understood. It has been shown in adult patients with cGVHD, there is an increase in resting energy expenditure. This increase may be due to pro-inflammatory cytokines such as TNF-a, IL-1 and IL-6 or alterations in levels of norepinephrine and glucagon. 7 It is likely that the body, in response to these inflammatory cytokines, is in a hypermetabolic state that can last for months and even years in patients with active disease. Combined with potential unwillingness and/or inability to consume adequate nutrition, long-term weight loss and malnutrition is the obvious consequence. It must be noted that in patients with multiorgan disease, the BMI nadir occurred much later after diagnosis of cGVHD as compared to patients with single-organ involvement. This suggests to us that weight loss is another manifestation of the ongoing inflammation in patients with multiorgan cGVHD.
Another possibility that must be considered is macro and micronutrient malabsorption. Studies in patients with Juvenile Dermatomyositis, which shares some clinical similarities to cGVHD, have shown that patients with endothelial damage have compromised absorption of oral prednisone. 8 This altered vascularity is seen in the capillaries of the nail beds and is directly correlated with altered vascularity of the endothelium. 9 Although it has not yet been tested in cGVHD, it is hypothesized that cGVHD mimics this pattern of inflammation, since Biedermann et al. 10 has shown that in biopsy specimen of patients with cGVHD there is loss of microvessels. This injury to microvessels could be occurring at the gut level causing an inflammation of the GI tract not unlike other stature from the beginning of transplant until expiration or until last available data. ---Indicates patients who expired from complications of their cGVHD; -indicates patient who is alive and stable with current cGVHD treatment; yy indicates patient who at the onset of cGVHD had significant weight loss but who has had improvement of cGVHD symptoms with early treatment. malabsorptive disorders. It is possible that early gut injury associated with acute GVHD 11 may persist throughout the chronic phase with few overt symptoms. This possible alteration in the mechanics of the GI tract may be causing malabsorption of macro and micronutrients contributing to continued weight loss trends. Increased intestinal permeability due to acute and chronic gut injury may also be contributing to malabsorption in these patients.
Jacobsohn et al. 12 also found that improvement in nausea, anorexia and oral sensitivity had no effect on reversal of weight loss in adults. In fact, it would be expected that cGVHD patients would have a stimulation of appetite as a side effect of steroid administration for treatment of cGVHD symptoms. In that series, despite treatment with significant levels of steroids in some cases, hyperphagia and concomitant weight gain did not occur in patients with extensive cGVHD, which would support the possibility of hypermetabolism and/or malabsorption. We suspect a similar mechanism in the pediatric patients presented herein.
Although height, weight and BMI are good first line indicators of nutritional problems, they should not be relied upon as the sole indicator of nutritional status in a child with cGVHD. White et al. 13 recently discovered that BMI grossly underestimated the severity of malnutrition in children in the transplant population when compared to body cell mass (BCM). According to their study, when evaluated with BMI alone, 14% of their transplant population was considered malnourished whereas 56% would be considered malnourished if using BCM. More sensitive markers of lean body and fat mass, as well as biochemical markers such as BCM, pre-albumin or insulin like growth factor may be useful for evaluating the overall nutritional status of the patient. However, growth charts remain a simple and effective way of identifying patients who may be at further nutritional risk. In the cases where the patients died from complications of cGVHD, these patients had a progressive decline in both weight and BMI from their transplant until the time of death. None of the three patients with more than one organ system involved who expired had any rebound in weight or BMI after transplant but rather had a steady decline in both through their disease course. All three of these patients suffered significant cGVHD that was refractory to multiple therapies. Although too small a group to conclude, decline in weight and BMI may have been likely contributors to morbidity and mortality in this group.
Regardless of the cause of weight loss, intervention is imperative, since pediatric oncology patients have improved survival with good nutritional status.
14 As a result of the frequency with which many practitioners see these patients, many do not realize the subtle changes that are occurring which add up to extended weight loss over a period of time. It is very important that this weight loss trend is identified early and proper intervention using the skills of a Registered Dietitian (RD) is attempted. 15 Nutritional support must be considered for the patient who is unable to take adequate nutrition orally to arrest or correct this weight loss trend. It is important that all members of the healthcare team are aware that weight loss and malnutrition are significant but poorly identified problems in the pediatric cGVHD population.
To summarize, we have shown that weight loss and decrease in BMI are very significant problems in pediatric patients with cGVHD, particularly those with multiorgan involvement. Unfortunately, this study was limited by its retrospective nature. Biochemical markers of nutritional status were not available and measures of intestinal permeability and cytokine levels are not routinely checked in our patient population. Therefore, it is difficult to truly determine the etiology of weight loss in these patients. Studies of intestinal permeability and resting energy expenditure are underway to further understand the etiology of weight loss in this population.
